Vitiligo Following Autologous Hematopoietic Stem Cell Transplantation.
作者信息
Nguyen James, Singh Navdeep, Afifi Salma, Giralt Sergio, Lacouture Mario E, Busam Klaus J, Hassoun Hani
机构信息
Multiple Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY.
Hospice and Palliative Care, Department of Medicine, North Shore University Hospital/Long Island Jewish Medical Center, New Hyde Park, NY.
出版信息
Clin Lymphoma Myeloma Leuk. 2020 Apr;20(4):e171-e173. doi: 10.1016/j.clml.2019.12.025. Epub 2020 Jan 9.
Abstract
摘要
相似文献
1
Vitiligo Following Autologous Hematopoietic Stem Cell Transplantation.自体造血干细胞移植后出现的白癜风
Clin Lymphoma Myeloma Leuk. 2020 Apr;20(4):e171-e173. doi: 10.1016/j.clml.2019.12.025. Epub 2020 Jan 9.
2
Outcomes of lenalidomide retreatment with novel triplet regimens in patients with multiple myeloma progressing on lenalidomide-based maintenance therapy.来那度胺维持治疗进展的多发性骨髓瘤患者采用新型三联方案重新使用来那度胺治疗的结果
Br J Haematol. 2021 May;193(3):e23-e26. doi: 10.1111/bjh.17393. Epub 2021 Mar 21.
3
Prolonged survival with increasing duration of lenalidomide maintenance after autologous transplant for multiple myeloma.多发性骨髓瘤自体移植后，来那度胺维持治疗持续时间延长可带来更长生存期。
Leuk Lymphoma. 2019 Feb;60(2):511-514. doi: 10.1080/10428194.2018.1473577. Epub 2019 Jan 8.
4
Lenalidomide and Vorinostat Maintenance after Autologous Transplantation in Multiple Myeloma: Long- Term Follow-Up.来那度胺与伏立诺他在多发性骨髓瘤自体移植后的维持治疗：长期随访
Biol Blood Marrow Transplant. 2020 Jan;26(1):44-49. doi: 10.1016/j.bbmt.2019.09.005. Epub 2019 Sep 10.
5
Clinical correlates and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving post-autologous stem cell transplantation lenalidomide maintenance therapy.接受自体干细胞移植后来那度胺维持治疗的多发性骨髓瘤患者中克隆性造血的临床相关性及预后影响
Am J Hematol. 2021 May 1;96(5):E157-E162. doi: 10.1002/ajh.26125. Epub 2021 Feb 23.
6
Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance.自体造血干细胞移植后接受来那度胺维持治疗的多发性骨髓瘤患者进行再接种是安全有效的。
Biol Blood Marrow Transplant. 2018 Apr;24(4):871-876. doi: 10.1016/j.bbmt.2017.12.795. Epub 2017 Dec 27.
7
Impact of lenalidomide on collected hematopoietic myeloid and erythroid progenitors: peripheral stem cell collection may not be affected.来那度胺对采集造血髓系和红系祖细胞的影响：外周血干细胞采集可能不受影响。
Leuk Lymphoma. 2019 Sep;60(9):2199-2206. doi: 10.1080/10428194.2019.1573367. Epub 2019 Mar 7.
8
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.达雷妥尤单抗、来那度胺、硼替佐米和地塞米松用于适合移植的新诊断多发性骨髓瘤：GRIFFIN 试验。
Blood. 2020 Aug 20;136(8):936-945. doi: 10.1182/blood.2020005288.
9
The efficacy and safety of modified bortezomib-lenalidomide-dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma.适合移植的新诊断多发性骨髓瘤患者中硼替佐米-来那度胺-地塞米松改良方案的疗效和安全性。
Eur J Haematol. 2020 Feb;104(2):110-115. doi: 10.1111/ejh.13349. Epub 2019 Nov 28.
10
Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma.德国骨髓瘤多中心组（GMMG）试验 HD6 的原理和设计：一项关于在新诊断骨髓瘤患者中 VRD 诱导/巩固和来那度胺维持中使用埃罗妥珠单抗的影响的随机 III 期试验。
BMC Cancer. 2019 May 28;19(1):504. doi: 10.1186/s12885-019-5600-x.
引用本文的文献
1
Deciphering Depigmentation: Mouse Models for Vitiligo Research.解读色素脱失：白癜风研究的小鼠模型
J Invest Dermatol. 2025 Sep;145(9):2135-2146. doi: 10.1016/j.jid.2025.06.1582. Epub 2025 Jul 23.
2
Vitiligo and Alopecia Areata After Donor Lymphocyte Infusions in a Child With Relapsed Acute Myeloid Leukemia.一名复发性急性髓系白血病儿童接受供体淋巴细胞输注后出现白癜风和斑秃。
Cureus. 2024 Jan 23;16(1):e52810. doi: 10.7759/cureus.52810. eCollection 2024 Jan.
本文引用的文献
1
Vitiligo under anti-programmed cell death-1 therapy is associated with increased survival in melanoma patients.抗程序性细胞死亡-1治疗下的白癜风与黑色素瘤患者生存率提高相关。
J Am Acad Dermatol. 2020 Mar;82(3):770-772. doi: 10.1016/j.jaad.2019.11.017. Epub 2019 Nov 14.
2
Vitiligo: Focus on Clinical Aspects, Immunopathogenesis, and Therapy.白癜风：关注临床方面、免疫发病机制和治疗。
Clin Rev Allergy Immunol. 2018 Feb;54(1):52-67. doi: 10.1007/s12016-017-8622-7.
3
Vitiligo.白癜风。
Lancet. 2015 Jul 4;386(9988):74-84. doi: 10.1016/S0140-6736(14)60763-7. Epub 2015 Jan 15.
4
Spontaneous graft versus host disease occurring in a patient with multiple myeloma after autologous stem cell transplant.自体造血干细胞移植后发生于多发性骨髓瘤患者的自发性移植物抗宿主病。
Am J Hematol. 2012 Feb;87(2):219-21. doi: 10.1002/ajh.22227. Epub 2011 Dec 21.
5
Depigmented macules following autologous bone-marrow transplant.自体骨髓移植后的色素脱失斑。
Arch Dermatol. 2011 Dec;147(12):1460-1. doi: 10.1001/archderm.147.12.1460.
6
Severe autologous GVHD after hematopoietic progenitor cell transplantation for multiple myeloma.多发性骨髓瘤造血祖细胞移植后发生的严重自体移植物抗宿主病。
Bone Marrow Transplant. 2009 Jan;43(2):169-77. doi: 10.1038/bmt.2008.295. Epub 2008 Sep 1.
7
Vitiligo after hematopoietic cell transplantation: six cases and review of the literature.造血干细胞移植后白癜风：6例病例及文献复习
Dermatology. 2008;216(4):349-54. doi: 10.1159/000117705. Epub 2008 Feb 20.
8
Vitiligo as a post-bone marrow transplantation complication.白癜风作为骨髓移植后的一种并发症。
J Pediatr Hematol Oncol. 2007 Jul;29(7):485-7. doi: 10.1097/MPH.0b013e31806210ef.
9
Generalized vitiligo after allogeneic bone marrow transplantation.异基因骨髓移植后泛发性白癜风。
Acta Derm Venereol. 2005;85(1):82-3. doi: 10.1080/00015550410021556.
10
Adoptive transfer of vitiligo after allogeneic bone marrow transplantation for non-Hodgkin's lymphoma.非霍奇金淋巴瘤异基因骨髓移植后白癜风的过继转移。
Lancet. 2000 Apr 15;355(9212):1334-5. doi: 10.1016/S0140-6736(00)02120-6.
Zotero 插件